Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein

Experimental Cell Research

Volumn 322, Issue 2, 2014, Pages 324-334

  Singh, Rumani ^a   Kalra, Rajkumar S ^a   Hasan, Kamrul ^a,d   Kaul, Zeenia ^b,c   Cheung, Caroline T ^a,e   Huschtscha, Lily ^b   Reddel, Roger R ^b   Kaul, Sunil C ^a   Wadhwa, Renu ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c OHIO STATE UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

CARF; DNA damage response; Mechanism; Senescence; Upregulation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BINDING PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HISTONE H2AX; MESSENGER RNA; PROTEIN CARF; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DNA SEQUENCE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SENESCENCE; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; STROMA CELL; UPREGULATION;

CARF; DNA DAMAGE RESPONSE; MECHANISM; SENESCENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL AGING; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DNA DAMAGE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SKIN; STROMAL CELLS; TELOMERIC REPEAT BINDING PROTEIN 2;

EID: 84896045476     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.01.022     Document Type: Article

References (28)

1. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
2. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
3. Chapman J.R., Jackson S.P. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep. 2008, 9:795-801.
4. Zhou J., Lim C.U., Li J.J., Cai L., Zhang Y. The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage. Cancer Lett. 2006, 243:9-15.
5. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
6. Di Micco R., Cicalese A., Fumagalli M., Dobreva M., Verrecchia A., Pelicci P.G., di Fagagna F. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle 2008, 7:3601-3606.
7. Hewitt G., Jurk D., Marques F.D., Correia-Melo C., Hardy T., Gackowska A., Anderson R., Taschuk M., Mann J., Passos J.F. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun. 2012, 3:708.
8. Kaul Z., Cesare A.J., Huschtscha L.I., Neumann A.A., Reddel R.R. Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. 2011, 13:52-59.
9. Herbig U., Jobling W.A., Chen B.P., Chen D.J., Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
10. Gire V., Roux P., Wynford-Thomas D., Brondello J.M., Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 2004, 23:2554-2563.
11. Wadhwa R., Takano S., Robert M., Yoshida A., Nomura H., Reddel R.R., Mitsui Y., Kaul S.C. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J. Biol. Chem. 1998, 273:29586-29591.
12. Kaul S.C., Yaguchi T., Taira K., Reddel R.R., Wadhwa R. Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp. Cell Res. 2003, 286:96-101.
13. Kaul S.C., Aida S., Yaguchi T., Kaur K., Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem. 2005, 280:39373-39379.
14. Hasan M.K., Yaguchi T., Sugihara T., Kumar P.K., Taira K., Reddel R.R., Kaul S.C., Wadhwa R. CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53. J. Biol. Chem. 2002, 277:37765-37770.
15. Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., Kaul S.C. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem. J. 2004, 380:605-610.
16. Hasan M.K., Yaguchi T., Harada J.I., Hirano T., Wadhwa R., Kaul S.C. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway. Int. J. Oncol. 2008, 32:663-671.
17. Hasan K., Wadhwa R., Kaul S.C. CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway. Ann. N. Y. Acad. Sci. 2007, 1100:312-315.
18. Hasan K., Cheung C., Kaul Z., Shah N., Sakaushi S., Sugimoto K., Oka S., Kaul S.C., Wadhwa R. CARF is a vital dual regulator of cellular senescence and apoptosis. J. Biol. Chem. 2009, 284:1664-1672.
19. Cheung C.T., Singh R., Yoon A.R., Hasan M.K., Yaguchi T., Kaul S.C., Yun C.O., Wadhwa R. Molecular characterization of apoptosis induced by CARF silencing in human cancer cells. Cell Death Differ. 2010, 18:589-601.
20. Sorensen C.S., Syljuasen R.G. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2011, 40:477-486.
21. Brown E.J. Analysis of cell cycle progression and genomic integrity in early lethal knockouts. Methods Mol. Biol. 2004, 280:201-212.
22. Evison B.J., Pastuovic M., Bilardi R.A., Forrest R.A., Pumuye P.P., Sleebs B.E., Watson K.G., Phillips D.R., Cutts S.M. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochem. Pharmacol. 2011, 82:1604-1618.
23. He G., Kuang J., Khokhar A.R., Siddik Z.H. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol. Oncol. 2011, 122:402-409.
24. Montano R., Chung I., Garner K.M., Parry D., Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol. Cancer Ther. 2011, 11:427-438.
25. Kaul Z., Yaguchi T., Chiura H.X., Kaul S.C., Wadhwa R. Quantum dot-based mortalin staining as a visual assay for detection of induced senescence in cancer cells. Ann. N. Y. Acad. Sci. 2007, 1100:368-372.
26. Wadhwa R., Sugihara T., Hasan M.K., Duncan E.L., Taira K., Kaul S.C. A novel putative collaborator of p19ARF. Exp. Gerontol. 2003, 38:245-252.
27. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999, 283:1321-1325.
28. de Lange T. Protection of mammalian telomeres. Oncogene 2002, 21:532-540.